Keyphrases
Combination Chemotherapy
100%
Phase II Trial
100%
Ifosfamide
100%
Vinblastine
100%
Gallium
100%
Metastatic Urothelial Carcinoma
100%
Gallium Nitride
66%
Remission
33%
Granulocytopenia
33%
Anemia
16%
Phase II Study
16%
Patient Demographics
16%
Adjuvant Therapy
16%
Blindness
16%
Treatment-related Mortality
16%
Thrombocytopenia
16%
Fever
16%
Novel Combinations
16%
Chemotherapy Regimen
16%
Objective Response
16%
Hypocalcemia
16%
Encephalopathy
16%
Cisplatin
16%
1,25-dihydroxycholecalciferol
16%
Calcitriol
16%
Subsequent Surgery
16%
Nephrectomy
16%
Pelvic Irradiation
16%
Nephrotoxicity
16%
Filgrastim
16%
Disease-free Status
16%
Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
16%
Mesna
16%
Medicine and Dentistry
Combination Chemotherapy
100%
Ifosfamide
100%
Transitional Cell Carcinoma
100%
Phase II Trials
100%
Vinblastine
100%
Gallium Nitrate
66%
Calcitriol
33%
Granulocytopenia
33%
Infusion
16%
Anemia
16%
Cisplatin
16%
Patient Population
16%
Adjuvant Therapy
16%
Thrombocytopenia
16%
Hypocalcaemia
16%
Brain Disease
16%
Nephrotoxicity
16%
Patient History of Nephrectomy
16%
Pelvic Radiotherapy
16%
Filgrastim
16%
Coenzyme M
16%
Recombinant Granulocyte Colony Stimulating Factor
16%
Chemotherapy
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Phase II Trials
100%
Ifosfamide
100%
Vinblastine
100%
Transitional Cell Carcinoma
100%
Gallium Nitrate
66%
Remission
33%
Calcitriol
33%
Granulocytopenia
33%
Anemia
16%
Cisplatin
16%
Thrombocytopenia
16%
Hypocalcaemia
16%
Nephrotoxicity
16%
Patient History of Nephrectomy
16%
Filgrastim
16%
Brain Disease
16%
Recombinant Granulocyte Colony Stimulating Factor
16%
Coenzyme M
16%
Diseases
16%